{"product_id":"tirzepatide","title":"Tirzepatide","description":"\u003cp\u003eSURMOUNT-1 (n=2,539): 22.5% mean weight loss at 72 weeks on 15 mg vs 2.4% placebo; 57% of participants achieved ≥20% weight loss. SURMOUNT-5 vs semaglutide 2.4 mg: 20.2% vs 13.7% weight reduction at 72 weeks, statistically superior. FDA-approved as Zepbound for obesity (November 2023) and Mounjaro for T2DM (May 2022). SURPASS programme (5 phase-3 trials): HbA1c reductions of 1.87–2.58% across T2DM populations. SURMOUNT-4 confirmed sustained weight loss and rebound on discontinuation.\u003c\/p\u003e\u003cp\u003eFor research reference only. Not a clinical recommendation.\u003c\/p\u003e","brand":"Peptique","offers":[{"title":"TBC","offer_id":47846667747491,"sku":"TIRZ-TBC","price":0.0,"currency_code":"AED","in_stock":false}],"url":"https:\/\/checkout.peptique.ae\/products\/tirzepatide","provider":"Peptique","version":"1.0","type":"link"}